Literature DB >> 33414407

A new risk factor indicator for papillary thyroid cancer based on immune infiltration.

Zhou Yang1, Xiyi Wei2, Yitong Pan3, Jingyuan Xu4, Yan Si5, Zhijun Min6, Bo Yu7,8.   

Abstract

Increasing evidence has indicated a close association between immune infiltration in cancer and clinical outcomes. However, related research in thyroid cancer is still deficient. Our research comprehensively investigated the immune infiltration of thyroid cancer. Data derived from TCGA and GEO databases were analyzed by the CIBERSORT, ESTIMATE, and EPIC algorithms. The CIBERSORT algorithm calculates the proportions of 22 types of immune cells. ESTIMATE algorithm calculates a stromal score to represent all stromal cells in cancer. The EPIC algorithm calculates the proportions of cancer-associated fibroblasts (CAFs) and endothelial cells (ECs), which are the main components of stromal cells. We analyzed the correlation of immune infiltration with clinical characteristics and outcomes of patients. We determined that the infiltration of CD8+ T cells improved the survival of thyroid cancer patients. Overexpression of immune checkpoints was closely related to the development of thyroid cancer. In general, stromal cells were associated with the progression of thyroid cancer. Interestingly, CAFs and ECs had opposite roles in this process. In addition, the BRAFV600E mutation was related to the upregulation of immune checkpoints and CAFs and the downregulation of CD8+ T cells and ECs. Finally, we constructed an immune risk score model to predict the prognosis and development of thyroid cancer. Our research demonstrated a comprehensive panorama of immune infiltration in thyroid cancer, which may provide potential value for immunotherapy.

Entities:  

Year:  2021        PMID: 33414407      PMCID: PMC7791058          DOI: 10.1038/s41419-020-03294-z

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  43 in total

1.  Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer.

Authors:  Lucas Leite Cunha; Elaine Cristina Morari; Ana Carolina Trindade Guihen; Daniela Razolli; Renê Gerhard; Suely Nonogaki; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Relat Cancer       Date:  2012-05-24       Impact factor: 5.678

2.  Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.

Authors:  Silvia Cantara; Eugenio Bertelli; Rossella Occhini; Marì Regoli; Lucia Brilli; Furio Pacini; Maria Grazia Castagna; Paolo Toti
Journal:  Endocrine       Date:  2019-02-14       Impact factor: 3.633

Review 3.  The changing epidemiology of thyroid cancer: why is incidence increasing?

Authors:  Riccardo Vigneri; Pasqualino Malandrino; Paolo Vigneri
Journal:  Curr Opin Oncol       Date:  2015-01       Impact factor: 3.645

Review 4.  Diagnosis and treatment of patients with thyroid cancer.

Authors:  Quang T Nguyen; Eun Joo Lee; Melinda Gingman Huang; Young In Park; Aashish Khullar; Raymond A Plodkowski
Journal:  Am Health Drug Benefits       Date:  2015-02

5.  Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer.

Authors:  Claire Germain; Sacha Gnjatic; Fella Tamzalit; Samantha Knockaert; Romain Remark; Jérémy Goc; Alice Lepelley; Etienne Becht; Sandrine Katsahian; Geoffray Bizouard; Pierre Validire; Diane Damotte; Marco Alifano; Pierre Magdeleinat; Isabelle Cremer; Jean-Luc Teillaud; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

6.  Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer.

Authors:  Luc de Chaisemartin; Jérémy Goc; Diane Damotte; Pierre Validire; Pierre Magdeleinat; Marco Alifano; Isabelle Cremer; Wolf-Herman Fridman; Catherine Sautès-Fridman; Marie-Caroline Dieu-Nosjean
Journal:  Cancer Res       Date:  2011-09-07       Impact factor: 12.701

7.  Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.

Authors:  Christina A von Roemeling; Laura A Marlow; Anthony B Pinkerton; Angela Crist; James Miller; Han W Tun; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2015-02-12       Impact factor: 5.958

8.  Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Authors:  Hyunju Lee; F Stephen Hodi; Anita Giobbie-Hurder; Patrick A Ott; Elizabeth I Buchbinder; Rizwan Haq; Sara Tolaney; Romualdo Barroso-Sousa; Kevin Zhang; Hilary Donahue; Meredith Davis; Maria E Gargano; Kristina M Kelley; Rona S Carroll; Ursula B Kaiser; Le Min
Journal:  Cancer Immunol Res       Date:  2017-10-27       Impact factor: 11.151

Review 9.  Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.

Authors:  Marina N Nikiforova; Yuri E Nikiforov
Journal:  Expert Rev Mol Diagn       Date:  2008-01       Impact factor: 5.225

10.  Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.

Authors:  Julien Racle; Kaat de Jonge; Petra Baumgaertner; Daniel E Speiser; David Gfeller
Journal:  Elife       Date:  2017-11-13       Impact factor: 8.140

View more
  10 in total

1.  Exploring the correlation analysis of immune microenvironment, mutation burden and prognosis of papillary thyroid carcinoma based on Estimate algorithm.

Authors:  Ying Wang; Ying He; Liubin Cao; Xiaoqing Peng; Zhenyong Gu; Jun Yan
Journal:  Gland Surg       Date:  2022-05

2.  The miR-199a-5p/PD-L1 axis regulates cell proliferation, migration and invasion in follicular thyroid carcinoma.

Authors:  Jianguang Lin; Yanru Qiu; Xueqin Zheng; Yijun Dai; Tianwen Xu
Journal:  BMC Cancer       Date:  2022-07-11       Impact factor: 4.638

3.  Thyroid Cancer Screening Using Tumor-Associated DN T Cells as Immunogenomic Markers.

Authors:  Shahnawaz Imam; Rodis D Paparodis; Shafiya Imtiaz Rafiqi; Sophia Ali; Azra Niaz; Abed Kanzy; Yara E Tovar; Mohammed A Madkhali; Ahmed Elsherif; Feras Khogeer; Zeeshan A Zahid; Haider Sarwar; Tamanna Karim; Nancy Salim; Juan C Jaume
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

4.  Immune Landscape and Classification in Lung Adenocarcinoma Based on a Novel Cell Cycle Checkpoints Related Signature for Predicting Prognosis and Therapeutic Response.

Authors:  Jian Yang; Zhike Chen; Zetian Gong; Qifan Li; Hao Ding; Yuan Cui; Lijuan Tang; Shiqin Li; Li Wan; Yu Li; Sheng Ju; Cheng Ding; Jun Zhao
Journal:  Front Genet       Date:  2022-05-11       Impact factor: 4.772

5.  Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer.

Authors:  Meiye Li; Jimei Zhang; Zongjing Zhang; Ying Qian; Wei Qu; Zhaoshun Jiang; Baochang Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-04       Impact factor: 5.555

6.  Single-Cell RNA Sequencing Revealed a 3-Gene Panel Predicted the Diagnosis and Prognosis of Thyroid Papillary Carcinoma and Associated With Tumor Immune Microenvironment.

Authors:  Zuoyu Chen; Yizeng Wang; Dongyang Li; Yuting Le; Yue Han; Lanning Jia; Caigu Yan; Zhigang Tian; Wenbin Song; Fuxin Li; Ke Zhao; Xianghui He
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

Review 7.  The functional roles of the circRNA/Wnt axis in cancer.

Authors:  Chen Xue; Ganglei Li; Qiuxian Zheng; Xinyu Gu; Zhengyi Bao; Juan Lu; Lanjuan Li
Journal:  Mol Cancer       Date:  2022-05-05       Impact factor: 41.444

Review 8.  Thyroid Cancer and Fibroblasts.

Authors:  Angelica Avagliano; Giuseppe Fiume; Claudio Bellevicine; Giancarlo Troncone; Alessandro Venuta; Vittoria Acampora; Sabrina De Lella; Maria Rosaria Ruocco; Stefania Masone; Nunzio Velotti; Pietro Carotenuto; Massimo Mallardo; Carmen Caiazza; Stefania Montagnani; Alessandro Arcucci
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

Review 9.  LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors.

Authors:  Natalia Sauer; Wojciech Szlasa; Laura Jonderko; Małgorzata Oślizło; Dominika Kunachowicz; Julita Kulbacka; Katarzyna Karłowicz-Bodalska
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

10.  Aging-related features predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.

Authors:  Ting Hong; Wei Su; Yitong Pan; Chenxi Tian; Guang Lei
Journal:  Front Immunol       Date:  2022-09-15       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.